{
    "clinical_study": {
        "@rank": "28262", 
        "acronym": "LASERBREAST1", 
        "brief_summary": {
            "textblock": "Demonstrate the effectiveness of laser in the treatment of cancerous lesions by\n      determinating with histological analysis of the specimen the percentage of tumor cells\n      remaining in the area treated by the laser"
        }, 
        "brief_title": "Local Treatment by Thermic Destruction of Primitive Breast Cancer", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Noninflammatory unilateral and unifocal breast cancer\n\n          -  Size </= 20mm (ultrasound measure)\n\n          -  Histological confirmation of cancer by biopsy grade status hormone and HER2.\n\n          -  Good delineation of the lesion on ultrasound.\n\n          -  Minimum distance of 5 mm between the tumor and the skin between the tumor and muscle.\n\n          -  Age between 18 and 80\n\n          -  ECOG performance status 0 or 1"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01706016", 
            "org_study_id": "2012-A00448-35", 
            "secondary_id": "2011/1773"
        }, 
        "intervention": {
            "intervention_name": "Thermic destruction of tissue by Laser using the Novilase device", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 12, 2012", 
        "location": {
            "contact": {
                "email": "garbay@igr.fr", 
                "last_name": "Jean Remy GARBAY, MD", 
                "phone": "+33 1 42 11 43 50"
            }, 
            "facility": {
                "address": {
                    "city": "Villejuif", 
                    "country": "France", 
                    "state": "Val de Marne", 
                    "zip": "94805"
                }, 
                "name": "Institut Gustave Roussy"
            }, 
            "investigator": {
                "last_name": "Jean Remy GARBAY, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Local Treatment by Thermic Destruction of Primitive Breast Cancer. Phase II: Feasibility and Effectiveness, Standardization of Procedures.", 
        "overall_contact": {
            "email": "garbay@igr.fr", 
            "last_name": "Jean Remy GARBAY, MD", 
            "phone": "+33 1 42 11 43 50"
        }, 
        "overall_contact_backup": {
            "email": "adunant@igr.fr", 
            "last_name": "Ariane DUNANT", 
            "phone": "+33 1 42 11 53 89"
        }, 
        "overall_official": {
            "affiliation": "Gustave Roussy, Cancer Campus, Grand Paris", 
            "last_name": "Jean Remy GARBAY, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Destruction of the carcinoma will be assess by histological analysis of the specimen.\nIf more than 10% of viables cancerous cells are remaining in the volume treated by laser, the procedure would be a fail", 
            "measure": "Effectiveness of laser treatment", 
            "safety_issue": "No", 
            "time_frame": "28 days after initial diagnosis"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01706016"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Life quality will be assess using the questionnaire QLQ-C30 breast module BR23-version 3", 
            "measure": "Life quality", 
            "safety_issue": "No", 
            "time_frame": "D-0 and before the surgery"
        }, 
        "source": "Gustave Roussy, Cancer Campus, Grand Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gustave Roussy, Cancer Campus, Grand Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}